{"filing":{"accession_number":"0001178913-26-004193","cik":"0001534248","ticker":"CMMB","company_name":"Chemomab Therapeutics Ltd.","form":"6-K","filing_date":"2026-08-19","report_date":"2026-06-30","primary_document":"zk2635899.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1534248/000117891326004193/zk2635899.htm"},"events":[{"id":28439,"run_id":26016,"accession_number":"0001178913-26-004193","anchor_item_number":"EX-99.3","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"The exhibit announces a definitive merger agreement between Chemomab and Scipher Medicine, with closing expected by year-end 2026. The merger is an all-stock transaction where Chemomab shareholders will own ~32% of the combined company valued at $150 million, plus a concurrent $30 million private placement and contingent value rights (CVRs) of up to $50 million. This is a material change of control and combination transaction that would significantly affect investor assessment of the registrant's future.","company_name":"Chemomab Therapeutics Ltd.","ticker":"CMMB","filing_date":"2026-08-19","form":"6-K","submitted_at":null,"items":[{"id":30387,"accession_number":"0001178913-26-004193","item_number":"EX-99.3","item_title":"exhibit_99-3.htm","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The exhibit announces a definitive merger agreement between Chemomab and Scipher Medicine, with closing expected by year-end 2026. The merger is an all-stock transaction where Chemomab shareholders will own ~32% of the combined company valued at $150 million, plus a concurrent $30 million private placement and contingent value rights (CVRs) of up to $50 million. This is a material change of control and combination transaction that would significantly affect investor assessment of the registrant's future.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-19T13:18:00.478066+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":30385,"accession_number":"0001178913-26-004193","item_number":"EX-99.1","item_title":"exhibit_99-1.htm","event_type":"periodic_interim","event_domain":"periodic","is_material":true,"confidence":0.95,"reasoning":"This exhibit is an interim condensed consolidated financial report for Chemomab Therapeutics Ltd. as of and for the six months ended June 30, 2026 (unaudited). The document contains balance sheets, statements of operations, statements of changes in equity, cash flow statements, and accompanying notes—the standard components of a periodic interim financial report. Critically, Note 1 discloses substantial doubt about the company's ability to continue as a going concern, citing recurring losses of ~$116 million, negative operating cash flows of $3.7 million for the period, and cash/deposits of only $6.7 million sufficient for less than 12 months of operations. This going-concern disclosure is material and would affect a reasonable investor's assessment, but the primary classification is the periodic interim report itself, which is deferred for separate processing rather than treated as a discrete event.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-19T13:18:00.478066+00:00","company_name":"Chemomab Therapeutics Ltd.","ticker":"CMMB","filing_date":"2026-08-19"},{"id":30386,"accession_number":"0001178913-26-004193","item_number":"EX-99.2","item_title":"exhibit_99-2.htm","event_type":"periodic_report","event_domain":"periodic","is_material":false,"confidence":0.85,"reasoning":"This exhibit is a cautionary note and operating/financial review section describing the company's drug candidate nebokitug, the proposed merger with Scipher Medicine, and the scientific rationale for RA development. It contains forward-looking statements, company overview, and strategic discussion but no discrete event disclosure, financial results, or material announcement. The content appears to be boilerplate disclosure accompanying a periodic or merger-related filing rather than a standalone event.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-19T13:18:00.478066+00:00","company_name":"Chemomab Therapeutics Ltd.","ticker":"CMMB","filing_date":"2026-08-19"},{"id":30387,"accession_number":"0001178913-26-004193","item_number":"EX-99.3","item_title":"exhibit_99-3.htm","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The exhibit announces a definitive merger agreement between Chemomab and Scipher Medicine, with closing expected by year-end 2026. The merger is an all-stock transaction where Chemomab shareholders will own ~32% of the combined company valued at $150 million, plus a concurrent $30 million private placement and contingent value rights (CVRs) of up to $50 million. This is a material change of control and combination transaction that would significantly affect investor assessment of the registrant's future.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-19T13:18:00.478066+00:00","company_name":"Chemomab Therapeutics Ltd.","ticker":"CMMB","filing_date":"2026-08-19"}]}